ERA

Download the full-sized PDF of Bone Targeting Salmon Calcitonin Analogues as Drug Delivery Systems for Bone DiseaseDownload the full-sized PDF

Analytics

Share

Permanent link (DOI): https://doi.org/10.7939/R3ST3D

Download

Export to: EndNote  |  Zotero  |  Mendeley

Communities

This file is in the following communities:

Graduate Studies and Research, Faculty of

Collections

This file is in the following collections:

Theses and Dissertations

Bone Targeting Salmon Calcitonin Analogues as Drug Delivery Systems for Bone Disease Open Access

Descriptions

Other title
Subject/Keyword
Bone Targeting
Salmon Calcitonin PEGylation,
Osteoporosis and Arthritis
Type of item
Thesis
Degree grantor
University of Alberta
Author or creator
Bhandari, Krishna H
Supervisor and department
Doschak, Michael R (Faculty of Pharmacy & Pharmaceutical Sciences)
Examining committee member and department
Löbenberg, Raimar (Faculty of Pharmacy & Pharmaceutical Sciences)
Mercer, Johns (Department of Oncology)
Klotz , Lars-Oliver (Faculty of Pharmacy & Pharmaceutical Sciences)
Velázquez, Carlos A (Faculty of Pharmacy & Pharmaceutical Sciences)
Barralet, Jake (Faculty of Dentistry, McGill University, Montreal Canada)
Department
Faculty of Pharmacy and Pharmaceutical Sciences
Specialization
Pharmaceutical Sciences
Date accepted
2012-08-27T13:21:54Z
Graduation date
2012-11
Degree
Doctor of Philosophy
Degree level
Doctoral
Abstract
The objective of this thesis was to design bone targeting salmon calcitonin (sCT) analogues as drug delivery systems for bone diseases. Non-PEGylated salmon calcitonin-bisphosphonate (sCT-BP) and PEGylated salmon calcitonin-bisphosphonate (sCT-PEG-BP) were investigated. sCT-BP conjugates were synthesized by initially reacting sCT with sulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate (sulfo-SMCC) in dimethylformamide (DMF) in presence of triethylamine (TEA) at room temperature. Thiolated bisphosphonate (thiol-BP) was then reacted with sCT-SMCC intermediate to generate sCT-BP conjugates. To synthesize sCT-PEG-BP, sCT was reacted with maleimide-PEG-N-hydroxy succinimidyl carboxy methyl ester (NHS-PEG-MAL) to generate sCT-PEG-MAL which was then reacted with thiol-BP to generate sCT-PEG-BP. Conjugates were characterized by tris-tricine SDS-PAGE. The number of BP per sCT molecule was determined by phosphate and sCT assays and the effect of PEG-BP or BP on sCT secondary structure was examined by Circular Dichroism (CD). sCT analogues were evaluated for in vitro bone mineral affinity and specificity using a binding assay for bone hydroxyapatite and several other calcium salts. Successful conjugation of sCT with BP and the effect of such conjugation on antibody binding ability of sCT was indirectly determined using ELISA. Conjugates were incubated with bone mineral in bone mineral coated osteologic plates. Presence of BP resulted into the binding of these conjugates on the bone mineral surface of these plates. sCT on such bound conjugates was then reacted with anti-sCT antibody. Finally, the intensity of the developed colour was measured. In vitro cell viability was evaluated in osteoclast (OC) precursor RAW 264.7 cells and sCT bioactivity and CTR binding potential was evaluated by in vitro intracellular cAMP stimulation assay in human T47D breast cancer cells. Similarly, in vivo activity was evaluated by determining the plasma levels of calcium after s. c. administration in normal, osteoporotic (OP) and osteoarthritic (OA) rats. Finally, efficacy in bone diseases like OP and adjuvant arthritis (AA) was studied using in- vivo micro-CT and a dose escalation study was performed in OP rats. Our results showed that the chemical coupling of BP or PEG-BP to sCT has a tendency to alter its secondary structure from a less stable and readily aggregation prone random coil orientation into a more stable and desirable alpha helical form without altering its receptor and antibody binding specificity. Bone targeting sCT analogues exhibited significantly greater affinity and specificity for bone mineral over unmodified sCT, retained strong sCT bioactivity and CTR binding affinity. They were non-toxic to bone marrow cells and exhibited comparable hypocalcaemic effect to that of sCT in normal rats. They decreased plasma calcium in OP and OA rats. Compared to marketed unmodified sCT, these analogues showed significantly improved efficacy in terms of preserving bone volume, BMD and trabecular micro-architecture in OP and AA rats. Bisphosphonate-mediated bone targeting of PEGylated or non-PEGylated sCT represents a new class of targeted antiresorptive compounds that have not previously been attempted. These bone targeting sCT analogues hold the promise of facilitating the delivery of sCT preferentially to skeletal bony tissues, thereby increasing its local concentration to bone surfaces, whilst maintaining sCT bioactivity and increasing efficacy.
Language
English
DOI
doi:10.7939/R3ST3D
Rights
Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of these terms. The author reserves all other publication and other rights in association with the copyright in the thesis and, except as herein before provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission.
Citation for previous publication

File Details

Date Uploaded
Date Modified
2014-05-01T00:34:28.952+00:00
Audit Status
Audits have not yet been run on this file.
Characterization
File format: pdf (Portable Document Format)
Mime type: application/pdf
File size: 10861987
Last modified: 2015:10:12 15:11:13-06:00
Filename: Bhandari_Krishna_Fall 2012.pdf
Original checksum: 6642b89b77528a39d8b3f26688899deb
Well formed: true
Valid: true
File title: Microsoft Word - Bhandari_Krishna_Fall 2012
File author: krishna
Page count: 254
Activity of users you follow
User Activity Date